Study guide

26.3 Palliative Care & End-of-Life Symptom Control

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

26.3 Palliative Care & End-of-Life Symptom Control

Key Takeaways Explain This Topic AI

The WHO Analgesic Ladder progresses from non-opioids (Step 1) to weak opioids (Step 2) to strong opioids (Step 3); oral morphine is the gold standard initial Step 3 opioid, with the breakthrough PRN dose strictly calculated as one-sixth (1/6th) of the total 24-hour regular background dose.

Converting oral morphine to subcutaneous morphine requires dividing the 24-hour oral dose by 2 (2:1 ratio); converting oral morphine to oral oxycodone requires dividing by 1.5 to 2.

Transdermal fentanyl patches are reserved strictly for stable, opioid-tolerant chronic pain (never for acute, unstable pain), with a 25 mcg/hour patch roughly equivalent to 60 mg/24 hours of oral morphine, requiring matrix patch replacement every 72 hours.

In severe renal impairment (eGFR <30 mL/min), toxic morphine metabolites (M3G causing allodynia/myoclonus, and M6G causing profound narcosis/respiratory depression) accumulate; fentanyl, alfentanil, or buprenorphine are the opioids of choice due to inactive hepatic metabolism.

In malignant bowel obstruction with colic, prokinetic agents (metoclopramide) are strictly contraindicated due to the risk of bowel perforation; management utilizes continuous subcutaneous antisecretory (hyoscine butylbromide, octreotide) and antiemetic (cyclizine, haloperidol) infusions.

Last updated: October 2026

Palliative medicine and terminal symptom management are essential components of the MRCP(UK) examination. Candidates must master the pharmacological principles of strong opioid titration, equianalgesic dose conversions, prescribing safety in renal failure, continuous subcutaneous infusions (syringe drivers), and targeted therapy for end-of-life symptoms.

1. Cancer Pain & The WHO Analgesic Ladder

The World Health Organization (WHO) three-step analgesic ladder provides the framework for systematic cancer pain pharmacotherapy:

Step 1 (Mild Pain): Non-opioid analgesics: Paracetamol (1 g QDS) ± Non-Steroidal Anti-Inflammatory Drugs ( NSAIDs , e.g. ibuprofen 400 mg TDS or naproxen 500 mg BD with a proton pump inhibitor).

Step 2 (Moderate Pain): Weak opioids: Codeine phosphate (30–60 mg QDS), dihydrocodeine (30 mg QDS), or tramadol (50–100 mg QDS) ± non-opioids.

Step 3 (Severe Pain): Strong opioids: Morphine , oxycodone , fentanyl , alfentanil , buprenorphine , or methadone ± non-opioids.

Adjuvant Analgesics (At Any Step):

Neuropathic Pain: Gabapentin, pregabalin, duloxetine, or amitriptyline.

Metastatic Bone Pain: NSAIDs, bisphosphonates (zoledronic acid), denosumab, and single-fraction external beam radiotherapy.

Visceral Capsular Distension / Raised ICP: Corticosteroids (dexamethasone 4–16 mg daily).

  • 2. Strong Opioid Titration & Conversion Rules
  • Oral Morphine: Gold-Standard Step 3 Analgesic

Initiation in Opioid-Naïve Patients: Begin with immediate-release oral morphine solution (Oramorph) 5 mg to 10 mg every 4 hours as required, or a low-dose modified-release oral morphine (e.g. MST Continus or Zomorph 10 mg to 20 mg twice daily ).

Breakthrough / PRN Pain Rule: The rescue dose for acute breakthrough pain is strictly one-sixth (1/6th) of the total 24-hour regular background oral morphine dose , prescribed every 2 to 4 hours as required. For example, if a patient takes 60 mg modified-release morphine twice daily (total 120 mg/24h), the breakthrough dose is 120 ÷ 6 = 20 mg 120 \div 6 = 20\text{ mg} 120 ÷ 6 = 20 mg immediate-release morphine.

Dose Titration: If breakthrough doses are required frequently (≥ 2–3 times per day), calculate the total morphine consumed over the preceding 24 hours (regular plus rescue doses) and increase the regular modified-release dose by 30% to 50%.

Opioid Equianalgesic Conversion Ratios

Conversion Step Ratio / Formula Clinical Worked Example

Oral Morphine to Subcutaneous Morphine Divide by 2 (2:1 ratio); (SC is twice as potent as oral) 60 mg oral morphine/24h = 30 mg SC morphine/24h

Oral Morphine to Oral Oxycodone Divide by 1.5 to 2 (1.5:1 to 2:1); (Oral oxycodone is ~1.5–2× more potent) 60 mg oral morphine/24h = 30–40 mg oral oxycodone/24h

Oral Oxycodone to Subcutaneous Oxycodone Divide by 2 (2:1 ratio); (SC oxycodone is twice as potent) 40 mg oral oxycodone/24h = 20 mg SC oxycodone/24h

Oral Morphine to Transdermal Fentanyl 60 mg/24h oral morphine ≈ 25 mcg/h patch 120 mg/24h oral morphine ≈ 50 mcg/h fentanyl patch

Breakthrough PRN Dose (Any Route) 1/6th of total 24-hour background dose Background 180 mg oral morphine = 30 mg oral PRN ; Background 60 mg SC morphine = 10 mg SC PRN

Transdermal Fentanyl & Buprenorphine Patches

Indications: Strictly indicated for stable, chronic pain in patients who are already opioid-tolerant . They are strictly contraindicated in acute, unstable, rapidly fluctuating pain due to slow onset and prolonged elimination half-life.

Pharmacokinetics: Highly lipophilic synthetic opioids that form a subcutaneous tissue reservoir. Following initial application, therapeutic serum concentrations take 12 to 24 hours to establish; conversely, after patch removal, drug continues to be absorbed from the dermal depot with an elimination half-life of 17 to 24 hours .

Replacement Frequency: Fentanyl matrix patches are replaced every 72 hours (3 days). Buprenorphine patches are replaced every 7 days (or 3–4 days depending on formulation).

Cautions: Systemic heat (pyrexia, heat pads, warm baths) markedly increases dermal blood flow and drug release, risking fatal opioid toxicity. Severe cachexia impairs cutaneous depot formation.

Opioid Prescribing in Renal Impairment (eGFR < 30 mL/min)

Renal clearance of opioids and their active metabolites is a critical source of MRCP examination questions:

Morphine: Metabolized in the liver by glucuronidation into Morphine-3-Glucuronide (M3G) and Morphine-6-Glucuronide (M6G) . M6G is a potent mu-opioid agonist responsible for analgesia and central narcosis; M3G has low opioid affinity but acts as an antagonist and causes central neurotoxicity. In renal impairment (eGFR < 30 mL/min), both metabolites accumulate dramatically, producing severe somnolence, profound respiratory depression, cognitive failure, hallucinations, myoclonus , and hyperalgesia. Avoid morphine in severe renal failure.

Oxycodone: Metabolized to noroxycodone and oxymorphone. While less toxic than morphine metabolites, they undergo renal elimination and can accumulate. Use with extreme caution and lengthened dosing intervals in mild-to-moderate renal impairment (eGFR 30–50 mL/min).

Drugs of Choice in Severe Renal Impairment (eGFR < 30 mL/min / Dialysis):

Fentanyl: Rapidly metabolized by hepatic CYP3A4 to inactive norfentanyl; negligible renal excretion of active drug. Safe in severe renal impairment.

Alfentanil: Ideal for continuous subcutaneous syringe drivers in renal failure due to rapid hepatic metabolism and inactive metabolites.

Buprenorphine: Metabolized hepatically and excreted primarily via the biliary/faecal route; unaffected by renal clearance.

Universal Co-Prescriptions with Strong Opioids

Constipation: Opioids bind mu-receptors in the myenteric plexus, suppressing peristalsis and intestinal secretions. Unlike nausea or sedation, tolerance to constipation never develops . A regular bowel regimen built on a stimulant laxative (e.g. senna ), with an osmotic laxative such as macrogol added if needed, is mandatory from day one.

Nausea: Occurs in up to 30% of patients during opioid initiation via stimulation of the chemoreceptor trigger zone (CTZ). Tolerance typically develops within 5 to 7 days . Co-prescribe a low-dose D2-antagonist (e.g. haloperidol 0.5–1.5 mg daily or metoclopramide 10 mg TDS) as required.

3. Syringe Drivers & Continuous Subcutaneous Infusions (CSCI)

An ambulatory syringe driver (e.g. McKinley T34 / CME BodyGuard) delivers medications by continuous subcutaneous infusion over a 24-hour period.

Indications for CSCI Initiation:

  • Persistent nausea, intractable vomiting, or severe gastrointestinal malabsorption;
  • Severe dysphagia (head and neck cancers, motor neuron disease, stroke);
  • Mechanical or functional malignant bowel obstruction;

Profound asthenia, altered consciousness, or comatose state in the terminal dying phase.

Technical Considerations: Diluted in water for injections or 0.9% sodium chloride. Typical infusion sites include the anterior chest wall, upper anterior arm, abdomen, or upper outer thigh (avoiding oedematous, irradiated, or broken skin).

  • 4. End-of-Life Symptom Management Palliative Symptom Management Pathways
  • |
  • +-------------------+---------------+-------------------+-------------------+
  • | | | |
  • Nausea & Vomiting Dyspnoea Secretions Delirium / Agitation
  • Chemical: - Fan therapy (trigeminal) - Repositioning - Identify causes
  • Haloperidol - Low-dose morphine SC (lateral) (urinary retention)
  • Stasis: - Midazolam (panic/anxiety) - Hyoscine - Mild: Haloperidol
  • Metoclopramide - Oxygen only if butylbromide - Severe: Midazolam

- Bowel Obstruction: SpO2 < 90% or Glycopyrronium - Refractory:

  • Buscopan, Octreotide - Avoid deep suction Levomepromazine
  • Nausea & Vomiting: Mechanism-Based Prescribing

Chemical / Metabolic (Opioids, Hypercalcaemia, Uraemia, Chemotherapy): Mediated via dopamine D2 and 5-HT3 receptors in the Chemoreceptor Trigger Zone (CTZ) in the area postrema. First-line: Haloperidol (1.5–3 mg/24h CSCI or 0.5–1.5 mg nocte) or levomepromazine (6.25–12.5 mg/24h CSCI).

Gastric Stasis / Autonomic Neuropathy (Hepatomegaly, Ascites, Opioids): Mediated via gastric mechanoreceptors. First-line: Prokinetic agents— Metoclopramide (30–60 mg/24h CSCI or 10 mg TDS) or domperidone (blocks peripheral D2 receptors, enhancing gastric motility).

Malignant Bowel Obstruction (MBO): Occurs in advanced ovarian, colorectal, and gastric malignancies.

CRITICAL CONTRAINDICATION: In established mechanical obstruction, prokinetic agents (metoclopramide) are strictly contraindicated because stimulating peristalsis against a closed obstruction causes agonizing colicky pain, bowel ischaemia, and risk of catastrophic bowel perforation .

MBO Regimen: Antispasmodic/antisecretory: Hyoscine butylbromide (Buscopan 60–120 mg/24h CSCI) ; Antiemetic: Cyclizine (150 mg/24h CSCI) or haloperidol; Antisecretory: Octreotide (somatostatin analogue, 300–600 mcg/24h CSCI) , which profoundly suppresses gastric, pancreatic, and biliary secretions; plus dexamethasone (8–16 mg SC) to reduce peritumoral oedema.

Raised Intracranial Pressure / Vestibular Nausea: Mediated via histamine H1 and muscarinic receptors. First-line: Cyclizine (150 mg/24h CSCI or 50 mg TDS) plus dexamethasone (8–16 mg daily).

Palliative Breathlessness (Dyspnoea)

Non-Pharmacological (First-Line): Directing a cool stream of air from a handheld electric fan across the lower face stimulates mechano-receptors in the trigeminal nerve (V2/V3 sensory distribution), which modulate respiratory centres in the brainstem, reducing the subjective perception of breathlessness. Positioning upright and open windows are complementary.

Pharmacological Therapy:

Low-Dose Opioids: Subcutaneous morphine 1.25 mg to 2.5 mg PRN (or oral morphine 2.5–5 mg PRN; or adding 10–20% to baseline 24-hour syringe driver). Low-dose opioids reduce central ventilatory drive, blunt excessive hypercapnic perception, and alleviate anxiety without causing respiratory depression.

Benzodiazepines: Subcutaneous midazolam 2.5 mg PRN (or sublingual lorazepam 0.5 mg) for associated acute anxiety or panic.

Supplemental Oxygen: Indicated only if the patient is demonstrably hypoxaemic (SpO₂ < 90%) ; in non-hypoxaemic patients, oxygen provides no superior benefit over a fan and causes nasal mucosal crusting.

Terminal Respiratory Secretions ("Death Rattle")

Pathophysiology: Inability of the semi-conscious or comatose patient to swallow or cough up normal salivary and bronchial secretions, resulting in turbulent, oscillating secretions in the hypopharynx during respiration.

Communication: Reassure the family that the sound does not indicate distress, choking, or suffocation to the dying patient.

Nursing Measures: Reposition into a lateral semi-prone position to encourage gravitational drainage; gentle oral toileting. Avoid aggressive deep suctioning, which induces gagging, coughing, and mucosal bleeding.

Antimuscarinic Pharmacotherapy: Must be administered early ; antimuscarinics inhibit new fluid production but do not clear pre-existing pooled fluid .

Hyoscine butylbromide (Buscopan 20 mg SC PRN or 60–120 mg/24h CSCI): Quarternary ammonium compound; does not cross the blood-brain barrier , thereby avoiding central sedation or paradoxical agitation.

Glycopyrronium bromide (200–400 mcg SC PRN or 600–1,200 mcg/24h CSCI): Also does not cross the blood-brain barrier; highly effective antisecretory agent.

Hyoscine hydrobromide crosses the blood-brain barrier and causes central sedation and delirium; therefore, it is generally less favoured.

Terminal Agitation & Restlessness

Screen for Reversible Triggers: Acute urinary retention (palpate bladder, perform bladder scan, insert urethral catheter), severe faecal impaction (perform gentle rectal exam), uncontrolled pain, acute hypoxaemia, or drug-induced akathisia.

Pharmacotherapy:

Midazolam (2.5–5 mg SC PRN or 10–30 mg/24h CSCI): First-line anxiolytic and sedative for terminal anxiety and distress.

Haloperidol (1.5–3 mg SC PRN or 3–5 mg/24h CSCI): Preferred for delirium with psychotic symptoms, paranoia, or hallucinations.

Levomepromazine (12.5–25 mg SC PRN or 25–50 mg/24h CSCI): Broad-spectrum sedative neuroleptic for refractory terminal agitation.